Last updated: Oct 3, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT04645160 | 1, 2 | Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | VEGFR -- tyrosine kinase inhibitor |
| NCT07715903 | 1 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | Proteasome -- proteasome inhibitor (carfilzomib) |
| NCT07854600 | 2 | A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer | Unknown mechanism |
| NCT07853690 | — | Histotripsy in Biliary Tract Cancer | PD-L1 -- immune checkpoint inhibitor (anti-PD-L1 antibody); PD-1 -- immune checkpoint inhibitor (anti-PD-1 antibody) |
| NCT07155525 | — | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas | Tissue adhesive glue -- cyanoacrylate adhesive |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 14 |
| Tianjin Medical University Cancer Institute and Hospital | 9 |
| Shanghai Zhongshan Hospital | 9 |
| Peking Union Medical College Hospital | 7 |
| West China Hospital | 5 |
Countries/regions with the most active trial sites for cholangiocarcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Nov 2026 | NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | CA242 -- antibody-drug conjugate (ADC) |
| Oct 7, 2026 | NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | Proteasome -- proteasome inhibitor (carfilzomib) |
| Sep 15, 2026 | NCT07632235 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | COX-2 -- selective inhibition (NSAID); PD-1 -- immune checkpoint blockade (monoclonal antibody) |
| Sep 2026 | NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | Glucocorticoid receptor -- anti-inflammatory and immunosuppressive effects (steroid hormone) |
| Aug 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| May 2026 | NCT07614061 | Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer | CD160 -- autologous antigen-specific T-cell therapy |
| Mar 27, 2026 | NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | IRAK4 -- small molecule inhibitor (Emavusertib) + chemotherapy (Gemcitabine, Cisplatin) + PD-L1 -- immune checkpoint inhibitor (Durvalumab) |
| Mar 2, 2026 | NCT07641036 | Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer | HER2 + CEACAM5 -- dual-target chimeric antigen receptor natural killer cells (CAR-NK) |
You've seen the cholangiocarcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.